IMMUNE COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (IC-MPGN)
Clinical trials for IMMUNE COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (IC-MPGN) explained in plain language.
Never miss a new study
Get alerted when new IMMUNE COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (IC-MPGN) trials appear
Sign up with your email to follow new studies for IMMUNE COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (IC-MPGN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare kidney patients: pegcetacoplan early access program opens
Disease control APPROVED_FOR_MARKETINGThis program offers early access to pegcetacoplan for people aged 12 and older with C3 glomerulopathy or primary IC-MPGN, rare kidney diseases that cause protein in the urine and active kidney damage. Participants must have a confirmed diagnosis and limited response to other trea…
Matched conditions: IMMUNE COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (IC-MPGN)
Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 08:34 UTC
-
New hope for rare kidney patients: long-term drug trial shows promise
Disease control OngoingThis study looks at the long-term safety and effectiveness of a drug called pegcetacoplan for people with two rare kidney diseases: C3 glomerulopathy (C3G) and immune-complex membranoproliferative glomerulonephritis (IC-MPGN). About 100 adults who already completed a one-year stu…
Matched conditions: IMMUNE COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (IC-MPGN)
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 22, 2026 14:04 UTC